Journal article

Statins: Neurobiological underpinnings and mechanisms in mood disorders

Adam J Walker, Yesul Kim, Igor Borissiouk, Rodolfo Rehder, Seetal Dodd, Gerwyn Morris, Andrew A Nierenberg, Michael Maes, Brisa S Fernandes, Olivia M Dean, Lana J Williams, Harris A Eyre, Sung-Wan Kim, Sophia Zoungas, Andre F Carvalho, Michael Berk



Statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) treat dyslipidaemia and cardiovascular disease by inhibiting cholesterol biosynthesis. They also have immunomodulatory and anti-inflammatory properties. Beyond cardiovascular disease, cholesterol and inflammation appear to be components of the pathogenesis and pathophysiology of neuropsychiatric disorders. Statins may therefore afford some therapeutic benefit in mood disorders. In this paper, we review the pathophysiology of mood disorders with a focus on pharmacologically relevant pathways, using major depressive disorder and bipolar disorder as exemplars. Statins are discussed in the context of these disorders, with parti..

View full abstract

University of Melbourne Researchers


Awarded by R.D. Wright NHMRC Biomedical Career Development Fellowship

Awarded by NHMRC

Funding Acknowledgements

The authors wish to dedicate this manuscript to the memory of Dr Igor Borissiouk. AJW is supported by a Trisno Family Research Fellowship, Deakin University. OMD is supported by an R.D. Wright NHMRC Biomedical Career Development Fellowship (1145634) . MB is supported by a NHMRC Senior Principal Research Fellowship (1156072) . LJW is supported by a NHMRC Emerging Research Fellow-ship (1174060) .